New drug shows promise in stroke recovery trial
NCT ID NCT07196605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding sodium sivelestat, a drug that reduces inflammation, to standard mechanical thrombectomy could improve outcomes in 20 stroke patients with large vessel occlusion. The drug aims to prevent 'futile recanalization,' where blood flow is restored but patients still do poorly. Results are expected to provide early evidence for a new anti-inflammatory approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sodium sivelestat
- What this could lead to
- If it works, this could point toward a new anti-inflammatory treatment to improve recovery after stroke thrombectomy.
- What could go wrong
- This is a very small, early exploratory study with only 20 patients and no comparison group, so results may not be reliable or generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital, Capital Medical University.
Beijing, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?